Ascendis Pharma AS (MEX:ASNDN)
MXN 3,851.44 (0%) Market Cap: 236.44 Bil Enterprise Value: 242.90 Bil PE Ratio: 27.94 PB Ratio: 26.03 GF Score: 37/100

Q1 2026 Ascendis Pharma A/S Earnings Call Transcript

May 07, 2026 / 12:00PM GMT
Operator

Good day, and thank you for standing by. Welcome to the first quarter Ascendis Pharma earnings conference call. (Operator Instructions) Please be advised that today's conference is being recorded. I will now hand the conference with your first speaker today, Chad Fugere, Vice President of Investor Relations. Please go ahead.

Chad Fugere Ascendis Pharma A;S;Vice President of Investor Relations

/-

Thank you, operator, and thank you, everyone, for joining our first quarter 2026 financial results conference call. I'm Chad Fugere, Vice President of Investor Relations at Ascendis Pharma. Joining me on the call today are Jan Mikkelsen, President and Chief Executive Officer; Scott Smith, Chief Financial Officer; Sherrie Glass, Chief Business Officer; and Jay Wu, EVP, and President, US Market.

Before we begin, I'd like to remind you that this conference call will contain forward-looking statements that are intended to be covered under the Safe Harbor provided by the Private Securities Litigation Reform Act. Examples of such statements may

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot